Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Diseases of the neuromuscular junction comprise a wide range of disorders. Antibodies, genetic mutations, specific drugs or toxins interfere with the number or function of one of the essential proteins that control signaling between the presynaptic nerve ending and the postsynaptic muscle membrane. Acquired autoimmune disorders of the neuromuscular junction are the most common and are described here. In myasthenia gravis, antibodies to acetylcholine receptors or to proteins involved in receptor clustering, particularly muscle-specific kinase, cause direct loss of acetylcholine receptors or interfere with the agrin-induced acetylcholine receptor clustering necessary for efficient neurotransmission. In the Lambert-Eaton myasthenic syndrome (LEMS), loss of the presynaptic voltage-gated calcium channels results in reduced release of the acetylcholine transmitter. The conditions are generally recognizable clinically and the diagnosis confirmed by serologic testing and electromyography. Screening for thymomas in myasthenia or small cell cancer in LEMS is important. Fortunately, a wide range of symptomatic treatments, immunosuppressive drugs, or other immunomodulating therapies is available. Future research is directed to understanding the pathogenesis, discovering new antigens, and trying to develop disease-specific treatments.

Original publication

DOI

10.1016/B978-0-444-63432-0.00024-4

Type

Journal article

Journal

Handb Clin Neurol

Publication Date

2016

Volume

133

Pages

447 - 466

Keywords

AChR, DELTA-P score, LEMS, MG, MuSK, acetylcholine receptor antibodies, autoimmunity, congenital myasthenia gravis, diagnosis, fatiguability, lambert-eaton myasthenic syndrome, muscle weakness, muscle-specific kinase antibodies, myasthenia gravis, neuromuscular junction disorder, seronegative myasthenia gravis, treatment, Autoantibodies, Electromyography, Humans, Neuromuscular Junction, Neuromuscular Junction Diseases, Receptors, Cholinergic